Business context and reporting period
The filing is Eyenovia, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2022; the request metadata names Hyperion DeFi, but the filing itself identifies Eyenovia (Nasdaq: EYEN). Eyenovia is a clinical-stage ophthalmic company developing drug-device combination products using its Optejet microdose delivery platform. It has no recurring revenue and is not yet profitable.
Financial results and liquidity
| Metric | Three months ended June 30, 2022 | Three months ended June 30, 2021 | Six months ended June 30, 2022 | Six months ended June 30, 2021 |
|---|---|---|---|---|
| Revenue | $0 | $2.0 million | $0 | $4.0 million |
| Gross profit | $0 | $1.2 million | $0 | $2.4 million |
| Research and development | $3.59 million | $3.68 million | $7.30 million | $8.01 million |
| General and administrative | $3.53 million | $2.30 million | $7.01 million | $4.54 million |
| Net loss | $7.24 million | $4.84 million | $14.58 million | $10.19 million |
| Basic and diluted loss per share | $0.22 | $0.19 | $0.46 | $0.40 |
The 2021 revenue and gross profit primarily reflect recognition of deferred license fees and related costs under the Arctic Vision agreement; no revenue was recognized in 2022. Gross margin is not meaningful for 2022 because revenue was zero.
- At June 30, 2022, cash and cash equivalents were $21.51 million, with an additional $7.88 million restricted as loan collateral. Working capital was $13.63 million; total assets were $35.61 million and stockholders’ equity was $23.61 million.
- Six-month operating cash use was $12.88 million, versus $9.90 million in 2021; investing cash use was $0.40 million. Financing provided $15.33 million, principally from equity offerings. Cash, cash equivalents and restricted cash together ended the period at $29.38 million.
- Notes payable were $7.73 million gross, or $7.43 million net of debt discount, all classified as current. The SVB loan repayment term was amended to 24 consecutive months, with the first payment extended to June 1, 2023. A separate D&O insurance loan matures August 24, 2022.
Material changes versus prior comparable periods
- Net loss increased by $2.40 million in Q2 and $4.39 million for the first half, reflecting the absence of prior-year license revenue and higher operating expenses.
- First-half R&D expense declined 8.8%, mainly because Mydcombi product testing was concentrated in 2021; personnel, stock compensation, and commercialization-related supplies increased.
- First-half G&A rose 55.6%, largely from professional fees, recruiting, new hires, and stock-based compensation.
- Shares issued and outstanding increased from 28.43 million at year-end 2021 to 33.62 million at June 30, 2022. The March registered offering generated approximately $15.0 million gross and included common shares and warrants; the ATM raised approximately $0.9 million net through June 30.
Outlook, risks, contingencies, and unusual items
- Going concern: Management states that substantial doubt exists about the company’s ability to continue as a going concern for at least one year from issuance of the financial statements. It expects continued operating cash outflows and says additional capital or licensing transactions will be needed; failure to obtain funding could require cuts to R&D and other costs. The filing does not provide a definitive cash runway estimate.
- Development outlook: Management anticipated VISION-2 top-line results in Q3 2022 and an FDA resubmission for Mydcombi in Q4 2022 after supplying additional non-clinical device information following an FDA complete response letter. The company also expected to reliably supply the CHAPERONE study with clinical product by Q3 2022. These are forward-looking statements, not reported outcomes.
- Funding after quarter-end: The company reported approximately $1.0 million in proceeds from 589,809 ATM shares sold after June 30. This adds liquidity but also dilutes shareholders.
- Commitments: Management listed next-12-month commitments of $4.5 million for accounts payable and accrued liabilities, $0.7 million for operating leases, up to approximately $1.5 million in potential executive severance, and $7.7 million in potential note payments. Additional lease commitments after 12 months were $0.8 million.
- Other notable matters: The CEO transition was announced July 27, with Michael Rowe effective August 1 and former CEO Sean Ianchulev becoming Executive Chairman. The company reported no material legal proceedings and no material changes to its previously disclosed risk factors. Management concluded disclosure controls were effective as of June 30, 2022.
Most important facts for investors to verify
- Whether the expected VISION-2 results, Mydcombi FDA resubmission, and CHAPERONE supply milestones occurred on the stated timelines.
- Current unrestricted cash, operating burn, financing needs, and progress in addressing the company’s stated going-concern doubt.
- Outstanding debt repayment terms, collateral restrictions on $7.88 million, and the timing of loan payments.
- Potential dilution from outstanding warrants and options, the ATM program, and subsequent share issuances.
- Whether licensing milestones, clinical progress, and any future commercialization generate meaningful revenue; the filing reports none for the first half of 2022.